ACAD
Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc
$ACAD reports Q1 increase in net sales and higher net loss due to pipeline development expenses
Acadia Pharmaceuticals announced an increase in first-quarter net sales to $118.5 million, driven by new patient starts across specialty pharmacy and specialty distribution channels. Although the company reported a net loss of $70 million due to higher research and development expenses, it completed significant milestones in its pipeline, such as the Phase 1 development program for ACP-204 and enrollment completion of the Phase 3 program for pimavanserin. Acadia also launched the first FDA-approved medicine for the treatment of Rett syndrome and was awarded a Rare Pediatric Disease Priority Review Voucher. Despite these positive developments, investors should remain cautious due to the volatility and uncertainty in drug development.
4mo ago
$ACAD